

Ananta Khurana

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/966968/publications.pdf>

Version: 2024-02-01

52
papers

927
citations

687220

13
h-index

477173

29
g-index

53
all docs

53
docs citations

53
times ranked

739
citing authors

#	ARTICLE	IF	CITATIONS
1	High terbinafine resistance in <i>Trichophyton interdigitale</i> isolates in Delhi, India harbouring mutations in the squalene epoxidase gene. <i>Mycoses</i> , 2018, 61, 477-484.	1.8	237
2	Antifungal resistance in dermatophytes: Recent trends and therapeutic implications. <i>Fungal Genetics and Biology</i> , 2019, 132, 103255.	0.9	113
3	A unique multidrug-resistant clonal <i>Trichophyton</i> population distinct from <i>Trichophyton mentagrophytes</i> / <i>Trichophyton interdigitale</i> complex causing an ongoing alarming dermatophytosis outbreak in India: Genomic insights and resistance profile. <i>Fungal Genetics and Biology</i> , 2019, 133, 103266.	0.9	93
4	Correlation of <i>In Vitro</i> Susceptibility Based on MICs and Squalene Epoxidase Mutations with Clinical Response to Terbinafine in Patients with Tinea Corporis/Cruris. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	90
5	Perspectives on misidentification of <i>Trichophyton interdigitale</i> / <i>Trichophyton mentagrophytes</i> using internal transcribed spacer region sequencing: Urgent need to update the sequence database. <i>Mycoses</i> , 2019, 62, 11-15.	1.8	40
6	Nonspecific genital ulcers. <i>Clinics in Dermatology</i> , 2014, 32, 259-274.	0.8	37
7	Indian association of dermatologists, venereologists and leprologists (IADVL) task force against recalcitrant tinea (ITART) consensus on the management of glabrous tinea (INTACT). <i>Indian Dermatology Online Journal</i> , 2020, 11, 502.	0.2	34
8	A pilot analysis of morphometric assessment of itraconazole brands using dermoscopy and its relevance in the current scenario. <i>Indian Dermatology Online Journal</i> , 2018, 9, 426.	0.2	25
9	Predicting a therapeutic cutoff serum level of itraconazole in recalcitrant tinea corporis and cruris: A prospective trial. <i>Mycoses</i> , 2021, 64, 1480-1488.	1.8	20
10	Parameters that determine dissolution and efficacy of itraconazole and its relevance to recalcitrant dermatophytoses. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 443-452.	1.3	18
11	The profile of cytokines (IL2, IFN3, IL4, IL10, IL17A, and IL23) in active alopecia areata. <i>Journal of Cosmetic Dermatology</i> , 2020, 19, 234-240.	0.8	18
12	Does oxidative stress correlate with disease activity and severity in vitiligo? An analytical study. <i>Journal of Cosmetic Dermatology</i> , 2021, 20, 352-359.	0.8	15
13	Genital lichen planus: An underrecognized entity. <i>Indian Journal of Sexually Transmitted Diseases and AIDS</i> , 2019, 40, 105.	0.1	15
14	Severe type 2 leprosy reaction with COVID-19 with a favourable outcome despite continued use of corticosteroids and methotrexate and a hypothesis on the possible immunological consequences. <i>International Journal of Infectious Diseases</i> , 2021, 103, 549-551.	1.5	14
15	Checkerboard Analysis To Evaluate Synergistic Combinations of Existing Antifungal Drugs and Propylene Glycol Monocaprylate in Isolates from Recalcitrant Tinea Corporis and Cruris Patients Harboring Squalene Epoxidase Gene Mutation. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0032121.	1.4	14
16	An exploratory pilot analysis of the optimal pellet number in 100%mg of itraconazole capsule to maximize the surface area to satisfy the Noyes-Whitney equation. <i>Journal of Dermatological Treatment</i> , 2020, 32, 1-7.	1.1	12
17	Does oxidative stress correlate with disease activity and severity in alopecia areata? An analytical study. <i>Journal of Cosmetic Dermatology</i> , 2022, 21, 1629-1634.	0.8	10
18	Leprosy stigma & the relevance of emergent therapeutic options. <i>Indian Journal of Medical Research</i> , 2020, 151, 1.	0.4	10

#	ARTICLE	IF	CITATIONS
19	Scientific rationale of antifungal drug combination, including oral itraconazole and terbinafine, in recalcitrant dermatophytoses. <i>Journal of Dermatological Treatment</i> , 2020, 31, 43-45.	1.1	8
20	A prospective study on patterns of topical steroids self-use in dermatophytoses and determinants predictive of cutaneous side effects. <i>Dermatologic Therapy</i> , 2020, 33, e13633.	0.8	8
21	Immunosuppressive agents for dermatological indications in the ongoing COVID-19 pandemic: Rationalizing use and clinical applicability. <i>Dermatologic Therapy</i> , 2020, 33, e13639.	0.8	7
22	Reinterpreting minimum inhibitory concentration (MIC) data of itraconazole versus terbinafine for dermatophytosis – time to look beyond the MIC data?. <i>Indian Journal of Dermatology, Venereology and Leprology</i> , 2018, 84, 61.	0.2	7
23	Complete cure of <i>Fusarium solani</i> sp. complex onychomycosis with Qs NdYAG treatment. <i>Dermatologic Therapy</i> , 2018, 31, e12580.	0.8	6
24	Atopic dermatitis: Clinical connotations, especially a focus on concomitant atopic undertones in immunocompromised/susceptible genetic and metabolic disorders. <i>Indian Journal of Dermatology</i> , 2016, 61, 241.	0.1	6
25	Hypermelanosis of the face and multiple naevoid hypertrichosis: Rare cutaneous mosaicism. <i>Australasian Journal of Dermatology</i> , 2014, 55, e29-32.	0.4	5
26	Lymphangioma circumscriptum treated with combination of Bleomycin sclerotherapy and Radiofrequency ablation. <i>Journal of Cosmetic and Laser Therapy</i> , 2018, 20, 326-329.	0.3	5
27	Re-emerging role of KOH smear examination in the era of recalcitrant dermatophytoses. <i>Dermatologic Therapy</i> , 2021, 34, e14891.	0.8	5
28	Multidrug resistant tinea corporis/cruris: response to voriconazole. <i>Journal De Mycologie Medicale</i> , 2022, , 101306.	0.7	5
29	Terbinafine induced liver injury may be asymptomatic: need for regular monitoring. <i>British Journal of Dermatology</i> , 2018, 178, 807-808.	1.4	4
30	A prospective study of anti-mullerian hormone and other ovarian and adrenal hormones in adult female acne. <i>Dermatologic Therapy</i> , 2020, 33, e13974.	0.8	4
31	Cutaneous side effects of hydroxychloroquine in health care workers in a COVID referral hospital – implications for clinical practice. <i>Journal of Dermatological Treatment</i> , 2020, , 1-3.	1.1	4
32	Rarity of cutaneous findings among asymptomatic to mildly symptomatic patients with COVID-19 admitted to a COVID care facility in Delhi, India: an observational study. <i>British Journal of Dermatology</i> , 2021, 185, 666-667.	1.4	4
33	Polidocanol Sclerotherapy in Pyogenic Granulomas. <i>Dermatologic Surgery</i> , 2022, 48, 72-75.	0.4	4
34	Late-onset naevus of Ota: a case series of six patients. <i>Clinical and Experimental Dermatology</i> , 2019, 44, 703-705.	0.6	3
35	Trimetazidine, a hitherto unreported cause of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome. <i>Contact Dermatitis</i> , 2021, 84, 208-210.	0.8	3
36	Clinical implications of antifungal drug susceptibility testing of dermatophytes. <i>Indian Dermatology Online Journal</i> , 2019, 10, 737.	0.2	3

#	ARTICLE	IF	CITATIONS
37	Indian Association of Dermatologists, Venereologists and Leprologists (IADVL) Task Force against Recalcitrant Tinea (ITART) Consensus on the Management of Glabrous Tinea (INTACT). Indian Dermatology Online Journal, 2020, 11, 502-519.	0.2	3
38	A study examining the combination of methotrexate and leflunomide with topical anthralin in pediatric alopecia areata—a possible steroid-free regimen with diverse mechanistic actions. Dermatologic Therapy, 2022, 35, .	0.8	3
39	Sepsis assessment in SJS/TEN: an important point overlooked?. Anais Brasileiros De Dermatologia, 2019, 94, 773-774.	0.5	2
40	Using cyclosporine in the COVID era: An emergent need for caution. Journal of the American Academy of Dermatology, 2020, 83, e315-e316.	0.6	2
41	Drug resistance to rifampicin in a case of steroid-dependent erythema nodosum leprosum and the therapeutic implications of resistance and reactions in leprosy. International Journal of Dermatology, 2021, 60, e407-e409.	0.5	2
42	Efficacy of bleomycin as a treatment modality in pyogenic granuloma: a case series. Dermatologic Therapy, 2021, 34, e15024.	0.8	2
43	Is there a rationale for the use of voriconazole in dermatophytosis in the absence of mycological and mutational data? An urgent need for antifungal stewardship. Clinical and Experimental Dermatology, 2021, 46, 1621-1623.	0.6	2
44	Congenital scars: a rare presentation of neonatal lupus. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2019, 104, F630-F630.	1.4	1
45	Hydroxychloroquine-induced erythroderma: A rare adverse effect of a commonly used drug. Dermatologic Therapy, 2020, 33, e14145.	0.8	1
46	A hypopigmented plaque on the face in a leprosy endemic area and the consequent histological confirmation of follicular mucinosis: an uncommon differential of leprosy in children. International Journal of Dermatology, 2020, 59, e471-e473.	0.5	1
47	Pulsed cyclophosphamide sans pulse steroids in recalcitrant pemphigus: An effective, economical but underutilized modality. Dermatologic Therapy, 2022, , e15392.	0.8	1
48	Refractory angiolymphoid hyperplasia with eosinophilia: Complete resolution with low dose thalidomide. Pediatric Dermatology, 0, , .	0.5	1
49	Description of a new pigmentary demarcation line (Type I). Clinical and Experimental Dermatology, 2019, 44, e145-e146.	0.6	0
50	Acquired dermal melanocytosis: Causing a rare but characteristic pattern of nasal alar pigmentation. Journal of Cosmetic Dermatology, 2020, 19, 3448-3450.	0.8	0
51	Not a Drug Rash!. Indian Dermatology Online Journal, 2020, 11, 99-100.	0.2	0
52	Asymmetrical ocular affliction in a case of recurrent erythema nodosum leprosum—an uncommon manifestation of leprosy in contemporary times. International Journal of Dermatology, 2022, , .	0.5	0